We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Historically, the CKD-HPT, HP, and HK disease space mainly consisted of reformulations of existing drugs and repurposed drugs from other disease markets.
Suven Life Sciences has been granted a patent each from Hong Kong, S.A.R., China and the US and two from India for treatment of disorders associated with neurodegenerative diseases.